Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ted Dawson MD, PhD

Ted M. Dawson MD, PhD

Professor, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland

Ted Dawson, MD, PhD, is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. His laboratory focuses on neurodegenerative diseases. He pioneered the role of nitric oxide (NO) in neuronal injury in stroke, glutamate excitotoxicity and Parkinson’s disease (PD). He elucidated the molecular mechanisms by which NO kills neurons through the actions of poly (ADP-ribose) (PAR) polymerase and discovered a unique cell death pathway designated parthanatos, in which PAR functions as an intracellular signaling molecule that induces the release of apoptosis inducing factor (AIF) and activation of the nuclease activity of macrophage migration inhibitor factor (MIF). His laboratory has made important discoveries on how neurons die in genetic and sporadic models of PD. Dr. Dawson’s discoveries are enabling clinical strategies for disease modifying therapies for PD and other neurodegenerative diseases.


Dr. Dawson is a founder and inventor of technology of Neuraly, Inc., that has optioned from Johns Hopkins University, which is now a subsidiary of D & D Pharmatech; Dr. Dawson holds shares of stock options as well as equity in D & D Pharmatech.

Recent Contributions to PracticeUpdate:

  1. GLP-1 RA Lixisenatide for Early-Stage Parkinson’s Disease